Combination approaches to combat multidrug-resistant bacteria

Trends in Biotechnology

Volumn 31, Issue 3, 2013, Pages 177-184

  Worthington, Roberta J ^a   Melander, Christian ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Antibiotic adjuvant; Antibiotic resistance

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; COMBINATION APPROACHES; COMBINATION THERAPY; LACTAMASES; SIGNALING PATHWAYS; TARGET RESISTANCE; TWO COMPONENT SYSTEMS;

ANTIBIOTICS; ENZYME INHIBITION;

DRUG THERAPY;

1 ETHYLIDENE 1,2,5,6,7,8,8A,8B OCTAHYDRO 5 METHOXY 2 OXOAZETO[2,1 A]ISOINDOLE 4 CARBOXYLIC ACID; 3 [[2 (2 AMINO 4 THIAZOLYL) 2 [[(1,4 DIHYDRO 1,5 DIHYDROXY 4 OXO 2 PYRIDINYL)METHOXY]IMINO]ACETYL]AMINO] 4 METHYL 2 OXO 1 AZETIDINESULFONIC ACID; 6 (5,6 DIHYDRO 8H IMIDAZO[2,1 C][1,4]OXAZIN 2 YLMETHYLENE) 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ARTEMISININ; AVIBACTAM; BACITRACIN; BAL 30367; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BIAPENEM; CEFUROXIME; CELECOXIB; CLAVULANIC ACID; COLISTIN; CYCLOOXYGENASE 2; FOSFOMYCIN; ME 1071; MONOBACTAM DERIVATIVE; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PROTEIN HISTIDINE KINASE; RESERPINE; TAZOBACTAM; TEICHOIC ACID; TEICOPLANIN; TETRACYCLINE; TICLOPIDINE; TUNICAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ADENYLATION; ANTIBIOTIC RESISTANCE; ARTHRITIS; BACTERIAL INFECTION; CARBOHYDRATE SYNTHESIS; DRUG SCREENING; ENZYME INHIBITION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENE EXPRESSION; GRAM NEGATIVE INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYDROLYSIS; INTRACELLULAR SIGNALING; INTRACELLULAR SPACE; KLEBSIELLA PNEUMONIAE; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ADJUVANTS, PHARMACEUTIC; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 84875261410     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2012.12.006     Document Type: Review

References (62)

1. Payne D.J. Microbiology. Desperately seeking new antibiotics. Science 2008, 321:1644-1645.
2. Klein E., et al. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 2007, 13:1840-1846.
3. Spellberg B., et al. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development. Infection 2007, 35:167-174.
4. Bassetti M., et al. New treatment options against gram-negative organisms. Crit. Care 2011, 15:215.
5. Spellberg B., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008, 46:155-164.
6. Conly J., Johnston B. Where are all the new antibiotics? The new antibiotic paradox. Can. J. Infect. Dis. Med. Microbiol. 2005, 16:159-160.
7. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000, 406:775-781.
8. Dolgin E. Sequencing of superbugs seen as key to combating their spread. Nat. Med. 2010, 16:1054.
9. Lane D. Designer combination therapy for cancer. Nat. Biotechnol. 2006, 24:163-164.
10. Richman D.D. HIV chemotherapy. Nature 2001, 410:995-1001.
11. Nosten F., White N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 2007, 77(6 Suppl.):181-192.
12. Mitchison D., Davies G. The chemotherapy of tuberculosis: past, present and future. Int. J. Tuberc. Lung Dis. 2012, 16:724-732.
13. Tamma P.D., et al. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 2012, 25:450-470.
14. Petrosillo N., et al. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 2008, 14:816-827.
15. Fischbach M.A. Combination therapies for combating antimicrobial resistance. Curr. Opin. Microbiol. 2011, 14:519-523.
16. Campbell J., et al. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem. Biol. 2011, 6:106-116.
17. Farha M.A., et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to beta-lactams. ACS Chem. Biol. 2012, [Epub ahead of print].
18. Sieradzki K., Tomasz A. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J. Antimicrob. Chemother. 1997, 39(Suppl. A):47-51.
19. Ball P. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections. Int. J. Antimicrob. Agents 2007, 30(Suppl. 2):S113-S117.
20. Walsh C. Where will new antibiotics come from?. Nat. Rev. Microbiol. 2003, 1:65-70.
21. Poirel L., Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 2006, 12:826-836.
22. Nordmann P., et al. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?. J. Antimicrob. Chemother. 2011, 66:689-692.
23. Petersen P.J., et al. Efficacy of piperacillin combined with the penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob. Agents Chemother. 2009, 53:1698-1700.
24. Paukner S., et al. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor. Antimicrob. Agents Chemother. 2009, 53:505-511.
25. Ehmann D.E., et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:11663-11668.
26. Page M.G., et al. In vitro and in vivo properties of BAL30376, a beta-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple beta-lactamases. Antimicrob. Agents Chemother. 2011, 55:1510-1519.
27. Lomovskaya O., et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 2001, 45:105-116.
28. Pages J.M., Amaral L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta 2009, 1794:826-833.
29. Lomovskaya O., Bostian K.A. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Biochem. Pharmacol. 2006, 71:910-918.
30. Kalle A.M., Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob. Agents Chemother. 2011, 55:439-442.
31. Sabatini S., et al. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors. J. Med. Chem. 2012, 55:3568-3572.
32. Gotoh Y., et al. Two-component signal transduction as potential drug targets in pathogenic bacteria. Curr. Opin. Microbiol. 2010, 13:232-239.
33. Gardete S., et al. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50:3424-3434.
34. Jo D.S., et al. Improved oxacillin treatment outcomes in experimental skin and lung infection by a methicillin-resistant Staphylococcus aureus isolate with a vraSR operon deletion. Antimicrob. Agents Chemother. 2011, 55:2818-2823.
35. Lee S., et al. Targeting a bacterial stress response to enhance antibiotic action. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14570-14575.
36. Adams M.D., et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 2009, 53:3628-3634.
37. Beceiro A., et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob. Agents Chemother. 2011, 55:3370-3379.
38. Kaczmarek F.M., et al. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE. Antimicrob. Agents Chemother. 2006, 50:3396-3406.
39. Srinivasan V.B., et al. Role of the two component signal transduction system CpxAR in conferring cefepime and chloramphenicol resistance in Klebsiella pneumoniae NTUH-K2044. PLoS ONE 2012, 7:e33777.
40. Matsushita M., Janda K.D. Histidine kinases as targets for new antimicrobial agents. Bioorg. Med. Chem. 2002, 10:855-867.
41. Barrett J.F., et al. Antibacterial agents that inhibit two-component signal transduction systems. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:5317-5322.
42. Rogers S.A., et al. Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob. Agents Chemother. 2010, 54:2112-2118.
43. Su Z., et al. Evaluation of 4,5-disubstituted-2-aminoimidazole-triazole conjugates for antibiofilm/antibiotic resensitization activity against MRSA and Acinetobacter baumannii. ChemMedChem 2011, 6:2243-2251.
44. Su Z., et al. Structural studies on 4,5-disubstituted-2-aminoimidazole-based biofilm modulators that suppress bacterial resistance to β-lactams. ChemMedChem 2012, 7:2030-2039.
45. Yeagley A.A., et al. N-Substituted 2-aminoimidazole inhibitors of MRSA biofilm formation accessed through direct 1,3-bis(tert-butoxycarbonyl)guanidine cyclization. Org. Biomol. Chem. 2013, 11:130-137.
46. Harris T.L., et al. Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus. Angew. Chem. Int. Ed. Engl. 2012, 51:11254-11257.
47. Worthington R.J., et al. Small molecule suppression of carbapenem resistance in NDM-1 producing Klebsiella pneumoniae. ACS Med. Chem. Lett. 2012, 3:357-361.
48. Chong C.R., Sullivan D.J. New uses for old drugs. Nature 2007, 448:645-646.
49. Mazumdar K., et al. The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:881-891.
50. Ejim L., et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 2011, 7:348-350.
51. Kristiansen J.E., et al. Reversal of resistance in microorganisms by help of non-antibiotics. J. Antimicrob. Chemother. 2007, 59:1271-1279.
52. Amaral L., Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int. J. Antimicrob. Agents 2012, 39:376-380.
53. Klitgaard J.K., et al. Reversal of methicillin resistance in Staphylococcus aureus by thioridazine. J. Antimicrob. Chemother. 2008, 62:1215-1221.
54. Bonde M., et al. Thioridazine affects transcription of genes involved in cell wall biosynthesis in methicillin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 2011, 318:168-176.
55. Poulsen M.O., et al. Thioridazine potentiates the effect of a beta-lactam antibiotic against Staphylococcus aureus independently of mecA expression. Res. Microbiol. 2012, 10.1016/j.resmic.2012.10.007.
56. Amaral L., et al. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 1996, 38:1049-1053.
57. Bettencourt M.V., et al. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 2000, 16:69-71.
58. Amaral L., et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!. Int. J. Antimicrob. Agents 2010, 35:524-526.
59. Miguel Viveiros L.A. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 2001, 17:225-228.
60. van Soolingen D., et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS ONE 2010, 5.
61. Lehtinen J., Lilius E.M. Promethazine renders Escherichia coli susceptible to penicillin G: real-time measurement of bacterial susceptibility by fluoro-luminometry. Int. J. Antimicrob. Agents 2007, 30:44-51.
62. Taylor P.L., et al. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 2012, 7:1547-1555.